arrow
E

Einav Nili Gal-Yam

chaim sheba medical center
H指数:26
被引数:6,262

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

InSituPREP enables 3D single-cell mapping of interaction-associated gene programs in the breast cancer tumor microenvironment

InSituPREP实现乳腺癌肿瘤微环境中与相互作用相关的基因程序的三维单细胞映射

2026-05-220
PRE
Vitiligo-like leucoderma following treatment with cyclin-dependent kinase 4 and 6 inhibitors: analysis of clinicopathological and immunohistochemical findings

接受 cyclin-dependent kinase 4 和 6 抑制剂治疗后出现的白癜风样色素脱失:临床病理及免疫组化结果分析

2025-12-010
PRE
Integrated spatial proteomic analysis of breast cancer heterogeneity unravels cancer cell phenotypic plasticity

乳腺癌异质性的整合空间蛋白质组学分析揭示了癌细胞表型可塑性

2025-11-250
OAAI
Deep phenotyping of health–disease continuum in the Human Phenotype Project

人类表型项目中健康-疾病连续体的深度表型分析

2025-07-150
PRE
Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

个体乳腺癌患者化疗耐药组图谱绘制揭示了动态转录适应性多样性

2025-04-280
OAAI
The impact of Human Epidermal growth factor Receptor 2 (HER2) expression by RT-PCR on tumor characteristics and outcome in estrogen receptor (ER) positive, HER2 negative early-stage breast cancer
2024-05-020
PRE
MORPHEUS Hormone Receptor-Positive Breast Cancer: interim analysis of a Phase Ib/II, study of fulvestrant ± atezolizumab and abemaciclib triplet treatment in patients metastatic disease
2024-05-020
PRE
Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial
2024-05-023
PRE
Clinical and Genomic Features of ER-Positive/HER2-negative Metastatic Breast Cancer in AURORA Molecular Screening Initiative (BIG 14-01): Mechanisms of Endocrine Therapy Resistance and Implications for Adjuvant Approaches
2024-05-020
PRE